Beckley PsyTech
Private Company
Company Overview
Beckley Psytech is dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines.
The company is focused on three distinct categories:
The company is focused on three distinct categories:
- “1st Generation” Psychedelic Medicine: Progressing innovative formulations and applications of well-characterised psychedelic agents such as psilocybin and other compounds
- “2nd Generation” Psychedelic Medicine: Developing known but under-researched psychedelic agents with potential clinical and patient access advantages over the first wave of psychedelic medicines
- “3rd Generation” Psychedelic Medicine: Designing New Chemical Entities (NCEs) that improve upon existing psychedelics by providing better clinical and cost-efficacy outcomes
Management Team
Cosmo Feilding Mellen
Director & CEO
Dr. Steve Wooding
Chief Scientific Officer
Tim Mason
Chief Development Officer
Michael Norris
Chief Financial Officer
Kalpana Sawant
Director of Clinical Operations